Neuropsychiatric Disorders: Pharmacological Aspects

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 25 February 2026 | Viewed by 858

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Exact Sciences and Natural Sciences, Institute of Interdisciplinary Research, “Alexandru Ioan Cuza” University of Iasi, 700057 Iasi, Romania
2. CENEMED Platform for Interdisciplinary Research, University of Medicine and Pharmacy “Grigore T. Popa”, 700115 Iasi, Romania
Interests: neurophysiology; neurodegeneration; animal behaviour; molecular biology; molecular genetics; oxidative stress
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As the Guest Editor of Pharmaceuticals, I am happy to invite you to contribute to this Special Issue, aimed at gathering relevant and good-quality scientific information, and facilitating communication between experts in the fields of neuropsychiatry, neurophysiology and pharmacology concerning innovative therapeutical measures in neuropsychiatric disorders. The interest of the current Special Issue is mainly focused on neuropsychiatry, but we also encourage interdisciplinary approaches, as well as fundamental research, with both animal studies and patient studies being welcome. The pharmacological aspects and inter-relations between pathological mechanisms and drug response could address any neuropsychiatric disorder, as defined by the DSM-V, and any known comorbidities, including cardiovascular disorders, coagulopathies and gastrointestinal disorders (including, but not limited to microbiome–gut–brain axis impairments).

We invite authors to contribute original research papers and reviews.

Dr. Ioana-Miruna Balmus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuropsychiatric disorders
  • DSM-V
  • pharmacodynamics
  • innovative therapies
  • animal models
  • neuropsychiatric patients
  • trauma and stress
  • neurodegeneration
  • affective disorders
  • neurodevelopmental disorders
  • schizophrenia
  • sleep disorders
  • comorbidities
  • cardiovascular
  • coagulopathies
  • gastrointestinal
  • microbiome–gut–brain axis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

27 pages, 1004 KB  
Article
Comparing the Metabolic, Systemic, and Neuropsychiatric Impacts of Olanzapine and Clozapine in Patients with Schizophrenia
by Nayef Samah Alharbi, Noha Alaa Hamdy, Esam M. Aboubakr, Mansour Alharbi, Mostafa A. Ali, Ghaleb Alharbi and Ahmed Ibrahim ElMallah
Pharmaceuticals 2025, 18(9), 1314; https://doi.org/10.3390/ph18091314 - 1 Sep 2025
Viewed by 468
Abstract
Background/Objectives: The clinical impact of antipsychotics on the human body remains inadequately investigated, hence we aimed to compere the effects olanzapine (OLZ) and Clozapine (CLZ) on different body systems. Methods: 48 patients and 24 healthy individuals were involved, and followed over six [...] Read more.
Background/Objectives: The clinical impact of antipsychotics on the human body remains inadequately investigated, hence we aimed to compere the effects olanzapine (OLZ) and Clozapine (CLZ) on different body systems. Methods: 48 patients and 24 healthy individuals were involved, and followed over six months. PANSS, metabolic, cardiovascular, inflammatory, and neuronal transmitter parameters were determined. Results: No significant difference was found between the effects of the two drugs on blood mineral and cardiovascular parameters, except for CK-MB, which showed a greater increase in the OLZ group than in the CLZ group. Both drugs increased the lipid profile and HbA1C levels, with the effect of CLZ being more prominent. Both drugs increased the patients’ body weights, with no significant difference between their effects. Regarding renal and hepatic functions, OLZ had a more notable effect on creatinine and albumin levels than CLZ, while AST and ALT showed markedly greater increases in the CLZ-treated group than in the OLZ-treated group. Regarding the effects on neurotransmitters and inflammatory mediators, both drugs increased serotonin and ghrelin levels, in addition to decreasing leptin concentrations, and decreased the inflammatory mediators IL-1β, IL-6, and –TNF-α, with the effect of OLZ being more prominent. Regarding therapeutic efficacy, CLZ was more effective at reducing general and negative symptoms than OLZ. Conclusions: The present study revealed that CLZ had a greater impact on metabolic parameters and better therapeutic efficacy in attenuating both general and negative symptoms, whereas OLZ had more detectable anti-inflammatory effects, aid determining the appropriate treatment for schizophrenic patients. Full article
(This article belongs to the Special Issue Neuropsychiatric Disorders: Pharmacological Aspects)
Show Figures

Figure 1

Back to TopTop